



Market Announcement

21 March 2022

ResApp Health Limited (ASX: RAP) – Suspension from Quotation

Description

The securities of ResApp Health Limited ('RAP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its COVID-19 study results.

Issued by

Barbara Lim

Adviser, Listings Compliance (Perth)

21 March 2022

Ms Barbara Lim
ASX Listings Compliance
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

By email: tradinghaltsperth@asx.com.au

Dear Barbara

RESAPP HEALTH LIMITED – VOLUNTARY SUSPENSION REQUEST

Further to the request on 17 March 2022 for the securities of ResApp Health Limited (“**Company**”) to be placed in trading halt, the Company hereby requests that its securities be placed in voluntary suspension in accordance with ASX Listing Rule 17.2, to finalise its announcement in relation to the Company’s COVID-19 study results.

The Company requests that the voluntary suspension ends on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by Tuesday 22 March 2022.

The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the suspension.

Yours faithfully



Nicki Farley
Company Secretary
ResApp Health Limited